Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash & Equivalents (2016 - 2025)

Amphastar Pharmaceuticals has reported Cash & Equivalents over the past 13 years, most recently at $170.2 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $170.2 million for Q4 2025, up 12.25% from a year ago — trailing twelve months through Dec 2025 was $170.2 million (up 12.25% YoY), and the annual figure for FY2025 was $170.2 million, up 12.25%.
  • Cash & Equivalents for Q4 2025 was $170.2 million at Amphastar Pharmaceuticals, down from $216.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for AMPH hit a ceiling of $266.8 million in Q3 2023 and a floor of $101.6 million in Q1 2021.
  • Median Cash & Equivalents over the past 5 years was $168.2 million (2022), compared with a mean of $166.0 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 85.25% in 2021 and later decreased 27.99% in 2024.
  • Amphastar Pharmaceuticals' Cash & Equivalents stood at $126.4 million in 2021, then grew by 23.54% to $156.1 million in 2022, then dropped by 7.56% to $144.3 million in 2023, then increased by 5.07% to $151.6 million in 2024, then grew by 12.25% to $170.2 million in 2025.
  • The last three reported values for Cash & Equivalents were $170.2 million (Q4 2025), $216.3 million (Q3 2025), and $187.7 million (Q2 2025) per Business Quant data.